Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 6 , Pages 955-969, December 2008

Molecular pathology of thyroid cancer: diagnostic and clinical implications

Department of Medicine and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA

There is now a reasonably good understanding of the key oncogenic events involved in the initiation and progression of thyroid cancer. Many of these are characteristic of certain tumor types, and their presence conveys diagnostic and prognostic information. It is not yet clear how this information will be applied to clinical practice. Based on preclinical evidence, mutations of genes encoding certain kinases may also predict response to specific tyrosine kinase inhibitors, although this has not yet been explored systematically in clinical trials.

Key words: thyroid cancer, pathogenesis, oncogene, RET, BRAF, RAS, molecular diagnostics, PTEN, PI3 kinase

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-690X(08)00112-7

doi:10.1016/j.beem.2008.09.017

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 6 , Pages 955-969, December 2008